291 related articles for article (PubMed ID: 12810622)
1. Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice.
Saukkonen K; Tomasetto C; Narko K; Rio MC; Ristimäki A
Cancer Res; 2003 Jun; 63(12):3032-6. PubMed ID: 12810622
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cyclooxygenase-2 causes regression of gastric adenomas in trefoil factor 1 deficient mice.
Thiel A; Narko K; Heinonen M; Hemmes A; Tomasetto C; Rio MC; Haglund C; Mäkelä TP; Ristimäki A
Int J Cancer; 2012 Sep; 131(5):1032-41. PubMed ID: 22034055
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase-2 and gastric carcinogenesis.
Saukkonen K; Rintahaka J; Sivula A; Buskens CJ; Van Rees BP; Rio MC; Haglund C; Van Lanschot JJ; Offerhaus GJ; Ristimaki A
APMIS; 2003 Oct; 111(10):915-25. PubMed ID: 14616542
[TBL] [Abstract][Full Text] [Related]
4. Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis.
Kato S; Ogawa Y; Kanatsu K; Okayama M; Watanabe T; Arakawa T; Takeuchi K
J Pharmacol Exp Ther; 2002 Nov; 303(2):503-9. PubMed ID: 12388629
[TBL] [Abstract][Full Text] [Related]
5. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
[TBL] [Abstract][Full Text] [Related]
6. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
[TBL] [Abstract][Full Text] [Related]
7. Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers.
Brzozowski T; Konturek PC; Konturek SJ; Sliwowski Z; Pajdo R; Drozdowicz D; Ptak A; Hahn EG
Microsc Res Tech; 2001 Jun; 53(5):343-53. PubMed ID: 11376495
[TBL] [Abstract][Full Text] [Related]
8. [Effects of cyclooxygenase-2 on formation and healing of acetic acid-induced gastric ulcer in rats].
Shen X
Zhonghua Yi Xue Za Zhi; 2001 Nov; 81(22):1380-3. PubMed ID: 11930633
[TBL] [Abstract][Full Text] [Related]
9. Anti-inflammatory effect of two isoforms of COX in H. pylori-induced gastritis in mice: possible involvement of PGE2.
Tanigawa T; Watanabe T; Hamaguchi M; Sasaki E; Tominaga K; Fujiwara Y; Oshitani N; Matsumoto T; Higuchi K; Arakawa T
Am J Physiol Gastrointest Liver Physiol; 2004 Jan; 286(1):G148-56. PubMed ID: 12958020
[TBL] [Abstract][Full Text] [Related]
10. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S
Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063
[TBL] [Abstract][Full Text] [Related]
11. Effects of celecoxib on acid-challenged gastric mucosa of rats: comparison with metamizol and piroxicam.
Berenguer B; Alarcón De La Lastra C; Motilva V; La Casa C; Herrerias JM; Pozo D; Calero MJ
Dig Dis Sci; 2004 Jun; 49(6):937-47. PubMed ID: 15309881
[TBL] [Abstract][Full Text] [Related]
12. Roles of endogenous prostaglandins and cyclooxygenase izoenzymes in mucosal defense of inflamed rat stomach.
Takeeda M; Hayashi Y; Yamato M; Murakami M; Takeuchi K
J Physiol Pharmacol; 2004 Mar; 55(1 Pt 2):193-205. PubMed ID: 15082878
[TBL] [Abstract][Full Text] [Related]
13. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
Geis GS
Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
[TBL] [Abstract][Full Text] [Related]
14. Suppression of Peutz-Jeghers polyposis by inhibition of cyclooxygenase-2.
Udd L; Katajisto P; Rossi DJ; Lepistö A; Lahesmaa AM; Ylikorkala A; Järvinen HJ; Ristimäki AP; Mäkelä TP
Gastroenterology; 2004 Oct; 127(4):1030-7. PubMed ID: 15480979
[TBL] [Abstract][Full Text] [Related]
15. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
Geis GS
J Rheumatol Suppl; 1999 Apr; 56():31-6. PubMed ID: 10225538
[TBL] [Abstract][Full Text] [Related]
16. Increased abundance of cyclooxygenase-2 correlates with vascular endothelial growth factor-A abundance and tumor angiogenesis in gastric cancer.
Yu HG; Li JY; Yang YN; Luo HS; Yu JP; Meier JJ; Schrader H; Bastian A; Schmidt WE; Schmitz F
Cancer Lett; 2003 May; 195(1):43-51. PubMed ID: 12767510
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
Howe LR; Subbaramaiah K; Brown AM; Dannenberg AJ
Endocr Relat Cancer; 2001 Jun; 8(2):97-114. PubMed ID: 11397667
[TBL] [Abstract][Full Text] [Related]
18. [Prophylactic effect of a selective COX-2 inhibitor celecoxib on carcinogen-induced gastric premalignant lesions in rats].
Tang BD; Zeng ZR; Hu PJ
Ai Zheng; 2006 Oct; 25(10):1205-9. PubMed ID: 17059761
[TBL] [Abstract][Full Text] [Related]
19. Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation.
Wallace JL; Zamuner SR; McKnight W; Dicay M; Mencarelli A; del Soldato P; Fiorucci S
Am J Physiol Gastrointest Liver Physiol; 2004 Jan; 286(1):G76-81. PubMed ID: 14665439
[TBL] [Abstract][Full Text] [Related]
20. Approach to angiogenesis inhibition based on cyclooxygenase-2.
Masferrer J
Cancer J; 2001; 7 Suppl 3():S144-50. PubMed ID: 11779086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
